Earth Science Tech Inc. (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, held its first annual meeting of stockholders virtually on August 31, 2026. Shareholders approved several key proposals that could significantly alter the company's capital structure and market presence, including authorizing the Board to pursue a reverse stock split if necessary to meet bid price requirements for an uplisting to a national exchange such as Nasdaq or NYSE.
The authorization of a reverse stock split is a critical step for companies seeking to uplist from over-the-counter markets to major exchanges, as it can help satisfy minimum share price thresholds. While the Board now has the discretion to execute the split within a 12-month period, CEO and Chairman Giorgio R. Saumat emphasized that he will not proceed unless it is in the best interest of shareholders. The move signals ETST's intent to elevate its profile and attract a broader investor base.
In another significant development, stockholders authorized the Board's Independent Special Committee to negotiate the retirement of the Series B Preferred Stock. This retirement would eliminate the company's current dual-class voting structure, simplifying governance and potentially making the company more attractive to institutional investors. The dual-class structure often concentrates voting power in the hands of a few, and its removal could enhance shareholder democracy and align the company with best practices for publicly traded firms on national exchanges.
Shareholders also ratified the appointment of Semple, Marchal & Cooper LLP as an independent registered public accounting firm, re-elected seven director nominees, and approved a new non-dilutive executive compensation framework. The compensation structure aims to align management incentives with shareholder interests without diluting existing equity, addressing a common concern among investors.
These approvals collectively represent a comprehensive strategy to strengthen ETST's corporate governance and financial standing. The potential uplisting to Nasdaq or NYSE would increase liquidity, visibility, and credibility, potentially lowering the cost of capital and attracting a wider range of investors. The retirement of the Series B Preferred Stock would streamline decision-making and could prevent conflicts of interest. The new executive compensation framework could help retain and motivate leadership while preserving shareholder value.
For a company operating in the competitive healthcare, pharmacy, and telemedicine sector, these moves are timely. As telemedicine continues to gain traction, ETST's ability to access public capital markets on more favorable terms could fuel growth and expansion. The company's newsroom at https://ibn.fm/ETST provides ongoing updates, and the full voting results are available via https://ibn.fm/HIqJ9.
Investors and market watchers will now look for further details on the timing of any reverse split and the outcome of negotiations to retire the Series B Preferred Stock. The success of these initiatives could determine whether ETST successfully transitions to a national exchange, a move that would mark a new chapter for the company and its shareholders.
